PF-06649751 efficacy and safety in early Parkinson’s disease: a randomized, placebo-controlled trial

by Robert Riesenberg, John Werth, Yao Zhang, Sridhar Duvvuri, David Gray
Published 2020-03-01

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment

by Stuart H. Isaacson, Robert A. Hauser, Rajesh Pahwa, David Gray, Sridhar Duvvuri
Published 2023-01-01

Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated

by U. Shivraj Sohur, David L. Gray, Sridhar Duvvuri, Yao Zhang, Kathleen Thayer, Gang Feng
Published 2018-10-01

Dopamine D₁ Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease

by Mechelle M. Lewis, Lauren J. Van Scoy, Sol De Jesus, Jonathan G. Hakun, Paul J. Eslinger, Julio Fernandez-Mendoza, Lan Kong, Yang Yang, Bethany L. Snyder, Natalia Loktionova, Sridhar Duvvuri, David L. Gray, Xuemei Huang, Richard B. Mailman
Published 2023-05-01